Methyl-β-cyclodextrin suppresses the monocyte-endothelial adhesion triggered by lipopolysaccharide (LPS) or oxidized low-density lipoprotein (oxLDL)

Context Recent studies demonstrated the anti-atherosclerotic efficacy of cyclodextrin. However, it remains unclear whether cyclodextrin exerts the anti-atherosclerotic effect via regulating monocyte-endothelial adhesion. Objective To answer that question by recruiting methyl-β-cyclodextrin (MβCD) as...

Full description

Saved in:
Bibliographic Details
Main Authors: Guo Chen (Author), Yun Zhou (Author), Wendiao Zhang (Author), Ying Qin (Author), Bo Wei (Author), Yanan Sun (Author), Yong Chen (Author)
Format: Book
Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_af14c7c844a7409d9fcce8b95d73097f
042 |a dc 
100 1 0 |a Guo Chen  |e author 
700 1 0 |a Yun Zhou  |e author 
700 1 0 |a Wendiao Zhang  |e author 
700 1 0 |a Ying Qin  |e author 
700 1 0 |a Bo Wei  |e author 
700 1 0 |a Yanan Sun  |e author 
700 1 0 |a Yong Chen  |e author 
245 0 0 |a Methyl-β-cyclodextrin suppresses the monocyte-endothelial adhesion triggered by lipopolysaccharide (LPS) or oxidized low-density lipoprotein (oxLDL) 
260 |b Taylor & Francis Group,   |c 2021-01-01T00:00:00Z. 
500 |a 1388-0209 
500 |a 1744-5116 
500 |a 10.1080/13880209.2021.1953540 
520 |a Context Recent studies demonstrated the anti-atherosclerotic efficacy of cyclodextrin. However, it remains unclear whether cyclodextrin exerts the anti-atherosclerotic effect via regulating monocyte-endothelial adhesion. Objective To answer that question by recruiting methyl-β-cyclodextrin (MβCD) as a cyclodextrin representative. Materials and methods Human umbilical vein endothelial cells (HUVECs) were not treated, or treated with 1 µg/mL liposaccharide (LPS) or 50 µg/mL oxidized low-density lipoprotein (oxLDL) for 12 h, 5 mM MβCD for 1 h, and LPS/oxLDL (1 and 50 µg/mL, respectively for 12 h) plus MβCD (5 mM for 1 h), respectively. The effects of MβCD on LPS/oxLDL-triggered monocyte-endothelial adhesion and related molecules in signalling pathways were evaluated via confocal microscopy, flow cytometry, RT-PCR, western blotting, and cell adhesion assay. Results MβCD with an IC50 of 27.66 mM (1 h treatment) exerted no significant cytotoxicity at ≤5 mM for ≤2 h. Compared with the control, both LPS and oxLDL induced an ∼2-3-fold increase in adhesion molecule expression (ICAM-1 and VCAM-1 at protein and mRNA levels) and NF-κB phosphorylation (p-NF-κB/pP65), an increase in IκB kinase (IKK), and a decrease in phosphorylated protein kinase B (p-Akt), respectively. Moreover, more monocytes (2-fold higher for LPS and 15% higher for oxLDL) were attached on LPS/oxLDL-stimulated HUVECs. 5 mM MβCD reversed the LPS/oxLDL-induced changes back to the control levels. Conclusions MβCD significantly suppresses the LPS/oxLDL-triggered monocyte-endothelial adhesion by downregulating adhesion molecule expression probably via LPS-IKK-NF-κB or oxLDL-Akt-NF-κB pathway. This study demonstrates a potential mechanism of the anti-atherosclerotic efficacy of cyclodextrin from the angle of monocyte-endothelial adhesion. 
546 |a EN 
690 |a cyclodextrins (cds) 
690 |a human umbilical vein endothelial cells (huvecs) 
690 |a thp-1 
690 |a atherosclerosis 
690 |a tumour 
690 |a nf-κb 
690 |a cell adhesion 
690 |a lipid raft 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmaceutical Biology, Vol 59, Iss 1, Pp 1036-1044 (2021) 
787 0 |n http://dx.doi.org/10.1080/13880209.2021.1953540 
787 0 |n https://doaj.org/toc/1388-0209 
787 0 |n https://doaj.org/toc/1744-5116 
856 4 1 |u https://doaj.org/article/af14c7c844a7409d9fcce8b95d73097f  |z Connect to this object online.